|
See related Orencia powd for inj information |
|
|
|
Manufacturer |
Bristol-Myers Squibb |
|
Distributor |
Hong Kong: DKSH |
|
Contents |
Abatacept |
|
Indications |
As monotherapy or in combination w/ DMARDs to reduce signs & symptoms, induce major clinical response, inhibit progression of structural damage & improve physical function in patients w/ moderately to severely active RA. As monotherapy or in combination with methotrexate to reduce signs & symptoms in childn ≥6 yr w/ moderately to severely active polyarticular juvenile idiopathic arthritis.
Click to view Orencia detailed prescribing infomation |
|
Dosage |
RA Adult >100 kg body wt 1,000 mg; 60-100 kg body wt 750 mg; <60 kg body wt 500 mg. Initially given at 2 & 4 wk after the 1st infusion then 4 wkly thereafter. Juvenile idiopathic arthritis Patients >75 kg Adult dose. <75 kg 10 mg/kg body wt. All doses to be administered as a 30-min IV infusion. Max dose: 1 g.
Click to view Orencia detailed prescribing infomation |
|
Overdosage |
View Orencia overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
[Click for Orencia detailed prescribing infomation] |
|
Warnings |
For additional cautionary notes to warn of the potential risk of using the medicine... click to view Orencia detailed prescribing infomation |
|
Special Precautions |
History of recurrent infections, underlying conditions predisposing to infections; chronic, latent or localized infections. Perform tuberculin skin test. Concomitant use of live vaccines w/in 3 mth of discontinuation. COPD. Pregnancy & lactation. Childn <6 yr. Elderly >65 yr.
Click to view Orencia detailed prescribing infomation |
|
Adverse Drug Reactions |
Headache, upper resp tract infection, nasopharyngitis & nausea; bronchitis, herpes zoster; pneumonia, localized infection; sinusitis, UTI, flu; cellulitis, diverticulitis, acute pyelonephritis; dizziness, HTN; COPD exacerbation, cough, rhonchi, dyspnea.
View ADR Monitoring Form |
|
Drug Interactions |
TNF antagonists, anakinra.
View more drug interactions with Orencia |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Orencia detailed prescribing infomation |
|
Storage |
View Orencia storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Orencia description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Orencia mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
ATC Classification |
L04AA24 - abatacept ; Belongs to the class of selective immunosuppressants. Used as immunosuppressants. |
